文献知网节
  • 记笔记
摘要:Lung cancer treatment has evolved significantly during the past decade but this disease remains the leading cause of cancer-associated mortality worldwide.Non-small cell lung cancer(NSCLC)accounts for almost 85%of all lung cancer cases[1].Epidermal growth factor receptor(EGFR)activating mutations and anaplastic lymphoma kinase(ALK) gene rearrangement in advanced non-small cell lung EGFR mutations and ALK rearrangement are observed frofn the cancer(NSCLC) represent the two oncogenic events with an impact on current clinical practice.Historically,the two molecular alterations have been viewed as mutually exclusive[2,3].However,recently,more and more concomitant clinic,which still lacks effective single-agent therapy.Therefore,it is urgent to develop a dual inhibitor of EGFR and ALK.We have discovered a highly potent dual kinase inhibitor JTS-1-39,which displayed strong antiproliferative effect against H197 S and H3122 cancer cell lines.JTS-1-39 significantly suppressed the tumor growth in xenograft model.The dual inhibitor JTS-1-39 might provide a novel therapeutic opportunity to treat EGFR-and ALK-codriven malignancies in NSCLC.
会议名称:

第11届世界华人药物化学研讨会(ISCMC 2018)

会议时间:

2018-08-24

会议地点:

中国河南郑州

  • 专辑:

    医药卫生科技

  • 专题:

    药学

  • 分类号:

    R96

  • 手机阅读
    即刻使用手机阅读
    第一步

    扫描二维码下载

    "移动知网-全球学术快报"客户端

    第二步

    打开“全球学术快报”

    点击首页左上角的扫描图标

    第三步

    扫描二维码

    手机同步阅读本篇文献

  • CAJ下载
  • PDF下载

下载手机APP用APP扫此码同步阅读该篇文章

下载:4 页码:114 页数:1 大小:56k

引文网络
  • 参考文献
  • 引证文献
  • 共引文献
  • 同被引文献
  • 二级参考文献
  • 二级引证文献
  • 批量下载
相关推荐
  • 相似文献
  • 读者推荐
  • 相关基金文献
  • 相关法规
  • 关联作者
  • 相关视频